Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Awarded $24M in 10x Genomics Patent Infringement Lawsuit

NEW YORK (GenomeWeb) – A jury has awarded Bio-Rad Laboratories $23.9 million in damages in the firm's patent infringement suit against 10x Genomics, the company announced yesterday.

The Federal District Court jury found that three US patents owned by the University of Chicago and exclusively licensed to Bio-Rad were willfully infringed by 10x. Specifically, the jury unanimously found that all single-cell and linked-read genomics products sold by 10x willfully infringed the patents, according to a statement from Bio-Rad.

In a separate action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10x in its products infringe patent rights owned by Bio-Rad, the firm said.

Bio-Rad filed a lawsuit in 2017, claiming infringement on a separate set of seven US patents.

In a statement to GenomeWeb, a 10x spokesperson said, "We strongly disagree with the verdict. We will immediately file an appeal."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.